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Kidney International (2016) 90, 943–949A cute kidney injury (AKI) and chronic kidney disease(CKD) each have a substantial global health careburden.1 The elderly with multiple morbidities are at
most risk, and the burden of both diseases is set to rise in line
with the demographic transition to older populations.2 There
is very limited understanding on how best to manage patients
with multiple health conditions.3 Historically, epidemiolog-
ical research on this group was challenging. Large cohorts
with many years of follow-up and high rates of retention were
needed, resulting in logistical complexities and substantial
ﬁnancial costs. This has changed with the availability of
computerized health care records. Data from electronic health
records (EHRs) have facilitated large epidemiological studies
to answer important questions that would otherwise not have
been possible.4
Speciﬁc characteristics of kidney disease can present chal-
lenges when using routine data for research. Kidney disease is
often asymptomatic, and diagnosis relies on blood and urine
tests. There are wide disparities in the availability of records of
renal function in EHRs.5 The patchy nature of renal data
means that epidemiologic research may be affected by biases.
There is increasing use of EHR data in research and as part of
performance management in health care. Recently, a reporting
guideline for observational studies of routinely collected
health care data was published, but no speciﬁc guidance exists
how to apply this guideline in the context of renal research.6
The aim of this mini review is to systematically explore the
issues that may arise in study design and interpretation of
kidney disease in routine data. We focus on primary care data,
as most patients with CKD are seen in the community setting.
We will not discuss ethical issues. An excellent in-depth dis-
cussion of AKI research using secondary care data has been
provided by others.7
In general, when reviewing EHR studies, it is useful to
consider what the perfect study to address the question would
be. Who should the perfect study focus on, and which data
items would be needed to control for confounding? Con-
trasting this perfect scenario with the reality of the databases
then clariﬁes the main limitations and potential biases.Who is captured in the database?
How patients access health care impacts on who is recorded
within routine data. For renal patients in particular, this may943
min i r ev i ew HI McDonald et al.: Methodological challenges when using routine EHRsreﬂect the cause and severity of their renal disease. For
example, patients with early CKD are more likely to be
identiﬁed and monitored in the primary care setting if they
have known risk factors such as diabetes mellitus, while those
receiving dialysis and under specialist care may only be
recorded in secondary care datasets. Some health systems
incentivize routine health checks (e.g., in occupational set-
tings), which may include kidney function markers. If
appropriate ethics approvals are in place, patient identiﬁers
can be used to collect further information from other routine
health data, such as hospitalization or dialysis registry data,
to investigate long-term outcomes according to baseline
function (examples given in Table 1).
In some settings, primary care practitioners are the gate-
keepers for access to specialized care. Therefore, in theory,
these data should be complete for every patient even without
linkage. However, this assumes good information ﬂow be-
tween primary and secondary care, and accurate recording of
secondary/tertiary care episodes. Whether this is indeed the
case is often unknown: for example, there are situations
where patients may be able to access specialist care directly
without ﬁrst seeing a primary care practitioner (e.g., patients
on renal replacement therapy). In health insurance–ﬁnanced
settings, the most complete data on individual patient care
may be found in medical claims data held by the insuranceTable 1 | UK example: Potential sources of anonymized
information about kidney disease
Primary care computerized health records
Databases are provided from speciﬁc primary care software providers;
contain information on clinical diagnoses, prescriptions, medical
procedures, and laboratory tests; and are traditionally coded with the
Read clinical coding system and include feedback from secondary
care. Examples include the Clinical Practice Research Datalink (CPRD)
and The Health Improvement Network (THIN).
Hospital records
Hospital Episode Statistics (HES) provide information on diagnoses (coded
with the International Classiﬁcation of Diseases, Tenth Revision [ICD-10])
and medical procedures related to all National Health Service–funded
hospital admissions in England. These data are entered by coders who
look at notes and discharge letters. They do not contain information on
laboratory results or inpatient prescriptions. Similar data to HES are
collected in Wales, Northern Ireland, and Scotland. HES data can be
linked to primary care records to provide more complete patient
information.
Laboratory records
It is possible to extract data directly from laboratories in the UK, as is being
done for acute kidney injury detection by the National Think Kidney’s
program. These data lack detailed patient information such as
underlying diagnoses or prescriptions.
Pharmacy dispensing records
Such data may provide valuable information on whether a patient
collected a prescribed drug from the pharmacy. However, there is little
information on comorbidity and no information on laboratory test
results. Data are usually linked to data containing information on renal
patients.
Disease registries and audit
As part of National Audit used for monitoring the quality of care and
commissioning, a range of disease registries have been set up to
capture key features of routine clinical care for speciﬁc disease entities.
This includes the UK Renal Registry, the National CKD Audit, and other
registries that may collect some renal data (e.g., Diabetes Registry).
944company. However, laboratory results will often not be
available within these data.
Initiation of renal replacement therapy is often used as a
proxy for kidney failure (estimated glomerular ﬁltration rate
[eGFR] <15 ml/min/1.73 m2) or end-stage renal disease.
However, it is important to understand the characteristics of
people who do not have access to care or are not recorded in
selected EHRs. For example, in some health-care settings,
patients have to pay for renal replacement therapy, for
example, in South Africa <50% of patients with end-stage
renal disease were accepted onto dialysis because of factors
related to poverty.8,9 Following the example of the US registry,
many registries deﬁne dialysis continuing beyond 3 months
as “chronic dialysis.” The UK renal registry initially only
collected data on patients who started and stayed on dialysis
for at least 3 months; consequently, patients with end-stage
renal disease who initiated dialysis but died before 3
months elapsed were missed. Patients may not want to start
renal replacement therapy and instead undergo conservative
management, but most renal registries do not collect this
information. In Canada, among those aged 85 years or older,
the proportion of untreated kidney failure was estimated to
be up to 10-fold higher than those treated.10
In order to avoid bias, only patients expected to be tested
as part of routine care for baseline kidney function and
who would have outcomes of interest recorded if these
happened should form part of the target population for study.
Having identiﬁed this target population of interest, the next
step is to check what information can be readily extracted and
whether the research question of interest can be addressed.
Who had renal function tests and why?
Testing is often triggered by acute illness and therefore will
not reﬂect “baseline” renal function. This differs from large
epidemiological studies that include patients who volunteer
to participate and typically are not acutely unwell. However,
particularly in the older population in whom most routine
tests are done, low eGFR measurements are usually not
transient.11
Testing may also be inﬂuenced by the clinical context, for
example, guidance recommends targeted testing for CKD in
those at most risk (people with diabetes, hypertension, and
cardiovascular disease).12 In the UK, in response to guideline
changes (Figure 1), there was an increase in recording of
serum creatinine over time in a cohort of people with diabetes
in primary care (Figure 2). Hence, the characteristics of pa-
tients who had renal function tested in the late 1990s may be
very different from patients routinely tested from 2007/2008
onward.
For CKD—should codes or original laboratory data be used?
There is a distinction to be made between having recorded
creatinine test results and a coded diagnosis of CKD. A coded
diagnosis relies on the general practitioner’s knowledge about
CKD as well as incentives to formally code the diagnosis.
There is wide variation in coding, with on average only 50%Kidney International (2016) 90, 943–949
1999 MDRD Study equation published
2004 QOF introduced, incentivizes annual kidney function
monitoring among patients with diabetes
2005 RCGP and Department of Health guidelines published
2006 QOF incentivized CKD register, phased introduction of
laboratory-specific standardization of serum creatinine tests
and eGFR reporting
2008 NICE CKD guidelines published
2009 CKD-EPI equation published
1997
2011
2002 K/DOQI classification of CKD published
Figure 1 | UK example: timeline of changes to the identiﬁcation
of CKD in UK primary care during 1997–2011.30 CKD-EPI, Chronic
Kidney Disease Epidemiology Collaboration; K/DOQI, Kidney Disease
Outcomes Quality Initiative; MDRD, Modiﬁcation of Diet in Renal
Disease; NICE, National Institute for Health and Care Excellence; QOF,
Quality and Outcomes Framework; RCGP, Royal College of General
Practitioners.
HI McDonald et al.: Methodological challenges when using routine EHRs m in i r ev i ewof patients meeting biochemical criteria for CKD being coded
as such.13 Deﬁning patient groups using CKD codes alone
results in the potential to miss a proportion of relevant pa-
tients to a variable extent over time.14–17 Therefore, most
large-scale epidemiologic research in EHRs relies on serum
creatinine results.Qual
int
100,000
80,000
60,000
40,000
20,000
0
19
97
–1
99
8
19
98
–1
99
9
19
99
–2
00
0
20
00
–2
00
1
20
00
–2
00
2
20
00
–2
0
Without creatinine result for the
Pa
tie
nt
s 
el
ig
ib
le
 fo
r s
tu
dy
in
cl
us
io
n 
th
ro
ug
ho
ut
 e
ac
h 
ye
ar
Figure 2 | UK example: completeness of serum creatinine recording a
ﬁnancial year. Patients were eligible for inclusion into the study if they
fulﬁlling quality criteria of reporting, aged 65 years or more, and had co
Kidney International (2016) 90, 943–949Techniques for laboratory measurement of serum creati-
nine have changed over time. In the UK, laboratory variation
in measurement of serum creatinine was addressed with the
phased introduction of laboratory-speciﬁc standardization
from 2006. Over time, laboratories have started to calibrate
creatinine assays to a reference assay using isotope-dilution
mass spectrometry, which needs to be considered in ana-
lyses. Therefore, eGFR calculated from serum creatinine levels
in EHRs may need adjustment for changes in creatinine
calibration depending on the time period covered in a study.18
If reported eGFR results are used, care needs to be taken on
which estimation formula (Modiﬁcation of Diet in Renal
Disease [MDRD], Chronic Kidney Disease Epidemiology
Collaboration [CKD-EPI]) was used for reporting.
Proteinuric kidney disease is generally not well recorded,
and there is substantial misclassiﬁcation because positive re-
sults are more likely to be encoded than negative results.5,15,16
For example, proteinuria levels detected on urinary test
strips may be recorded as free text in the patient’s medical
notes but not formally coded in the EHRs, and therefore the
information is harder to obtain. In routine care, more sen-
sitive and better quantiﬁed tests such as the urinary albumin–
creatinine ratio are usually limited to targeted populations
known to be at high risk such as those with diabetes.15 Pre-
vious studies using routinely collected data have used single
time point measures of urinary protein or albuminuria, often
incorporating different methods of quantiﬁcation.4,19 Most
studies using outpatient laboratory data will not be able to
quantify the precise timing of when the sample was taken
(e.g., morning urine versus random urine).
For AKI— should codes or original laboratory data be used?
A universal deﬁnition and staging system for AKI was
ﬁrst introduced in 2004.20 Its aim was to present AKI as a
spectrum, encouraging earlier detection and intervention.ity outcomes framework
roduced 1 April 2004
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des consistent with having diabetes.30
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min i r ev i ew HI McDonald et al.: Methodological challenges when using routine EHRsKnowledge and awareness of the diagnostic criteria for AKI
among clinicians in primary and secondary care is changing
rapidly but has been limited until recently. While it has been
poorly investigated to date, it is likely that coding for AKI
(or acute renal failure) in primary care reﬂects the situation
in secondary care: coding captures a fraction of AKI cases
deﬁned by biochemical criteria and is particularly likely to
miss less severe cases.21 Accuracy of coding of abnormal renal
function also relies on the physician being able to distinguish
between AKI and CKD.
The need for clinical recognition can be removed by
applying AKI staging criteria to biochemical data.22 However,
AKI algorithms may misclassify worsening CKD as AKI; in a
hospital setting, 14% of those identiﬁed had CKD rather than
AKI.21 As the AKI algorithm was developed for use with
inpatient laboratory data, it should be used with caution in
community data. Compared with a hospital setting, serum
creatinine measurements in the community are likely to be
separated by longer intervals. This increases the likelihood of
misclassifying a gradual decline in renal function as AKI. In
addition, it is not possible to apply AKI staging criteria to a
single serum creatinine measure without knowledge of a
previous and reliable baseline. Patients with available baseline
renal function are unlikely to be representative of the general
population; they are likely to be either people with chronic
conditions that have prompted testing or those who engage
more with health care. Previously healthy individuals are
less likely to have recent baseline serum creatinine results
available.
What other data items are needed for confounding control
and are these items captured in the database?
Similar to what was discussed for renal disease, guideline
changes and performance incentives may result in changes
to how information on other key variables is recorded over
time. For example, a ﬁnancially incentivized change to the
recommended management of patients diagnosed with
depression led general practitioners to use fewer depression
diagnosis codes and use nonspeciﬁc symptom codes instead.23
If such issues are not considered, narrow deﬁnitions may
result in incomplete capture of key variables.
Certain items may not be recorded at all as they are outside
the remit of care. For example, although in the UK most
prescriptions are issued by primary care physicians, key drugs
of interest to renal physicians (such as erythropoietin, certain
immunosuppressant drugs, and biologics [e.g., rituximab])
are commissioned and prescribed in secondary care, which
means that primary care data on these drugs will be incom-
plete. Another example is nonsteroidal anti-inﬂammatory
drug use, which cannot be captured accurately in settings
where these drugs are freely available over the counter.
Finally, when extracting dates of diagnoses of certain dis-
eases, it is important to consider timing relative to registration
with a doctor. Disease symptoms may lead some patients to
join with a new practice, biasing observed incidence rates
upward for the time shortly after registration. Preexisting946comorbidities may also be entered without distinction from
new diagnoses during early patient visits in which previous
medical history is established. Lewis et al.24 found that this
increased incidence rate following new patient registration
returned to baseline within 6 months for most acute condi-
tions and within a year for most chronic conditions. This
means that analyses of incident disease need to have a start
time of observation at least 6 months after registration, and a
year is commonly used.
Can potential biases when using EHRs be mitigated for renal
analyses?
In this section, the 2 most common observational study de-
signs (case-control, cohort) will be used as a device to discuss
common biases in renal EHRs research, with eGFR as a
baseline variable and AKI as an outcome variable (Table 2).
Minimizing confounding. Testing for eGFR and protein-
uria in the general population is often inﬂuenced by clinical
characteristics. As long as the researcher investigates these
characteristics and understands testing incentives over time,
it is possible to adapt the study design and analyses for these
confounding factors. If all test results are used, adjustment
for health status is needed to avoid residual confounding,
but aspects of health status may be poorly captured in
EHRs. Alternatively, restriction of the epidemiologic study to
a cohort with higher cardiovascular risk who are expected to
be routinely tested ensures that the indication for the
baseline renal function test is independent from its test
result.
Understanding how clinicians prescribe is key to inter-
preting ﬁndings and spotting potential sources of residual
confounding. For example, certain medications may be pre-
scribed more or less commonly in patients with CKD,
thus presence or absence of a drug prescription may be a
surrogate marker of underlying kidney function. Angiotensin-
converting enzyme inhibitors may, for example, be prescribed
more commonly in people with proteinuria on dipstick
testing. However, if proteinuria is recorded less completely
than angiotensin-converting enzyme inhibitor prescriptions,
then analyses using recorded data will be subject to residual
confounding by uncoded proteinuria.
Avoiding exposure misclassiﬁcation and immortal time
bias. In traditional epidemiological studies of the effect of
CKD on outcomes, the deﬁnition of CKD is often based on a
single measurement of serum creatinine at baseline when the
study participant is in steady-state. However, identifying CKD
based on a single estimate of GFR in clinical records will tend
to overestimate CKD prevalence, because a single impaired
GFR may also be caused by AKI or because the test may have
been prompted by ill health.25 Therefore, the clinical classi-
ﬁcation of CKD requires that impaired renal function persists
for at least 3 months for CKD diagnosis. However, if 2 results
are required to deﬁne time-updated CKD status in epidemi-
ological studies, the time between the ﬁrst and second results
must be handled with care to avoid immortal time bias. Pa-
tients have to be alive in order to attend clinic and have theKidney International (2016) 90, 943–949
Table 2 | Summary of potential biases that may arise in an example study of the association between baseline eGFR and AKI
Potential biases
Immortal time bias Selection bias Competing risk
Outcome
misclassiﬁcation Reverse causality
Cohort study Allocating time that does
not have outcome
events systematically
to 1 exposure group.
Differential
completeness of
follow-up, because
speciﬁc subgroups do
not remain in the
study population or
attend facility that
collects outcome data.
Censoring of follow-up
time differentially by
exposure status.
Outcome is not
systematically
identiﬁed and may be
differential or
nondifferential.
Outcome data affect
exposure data
differentially.
Example Only coding patients
with 2 measurements
of eGFR <60 as having
CKD and starting
follow-up at ﬁrst eGFR
measurement. This
assumes that patients
do not have AKI after a
single eGFR
measurement.
Patients with AKI who do
not require chronic
dialysis may not be
recorded in renal
registry, or cannot
afford hospitalization
or dialysis, and
therefore are not
recorded in the
registry.
When exploring AKI
rates in the very
elderly consider that
study participants
with more advanced
stages of CKD may
die before having
AKI.
Coded AKI on discharge
is used as an outcome
variable.
Differential
misclassiﬁcation
occurs if doctors may
be more aware of AKI
if patient has
underlying known
kidney disease.
AKI is deﬁned by coded
admission; however,
AKI occurred earlier
and the primary care
physician took blood
to measure eGFR
during the acute
illness, and then
referred patient to
hospital.
Suggested
mitigation
for example
Use last carried forward
method (Figure 3), or
deﬁne CKD status at
the second time-point
comparing with
people who have a
similar time of follow-
up between the ﬁrst
and second
measurements.
Restrict study population
to those who can
afford health care and
use laboratory values
at admission and
compare with previous
values >1 week before
admission.
Competing risk
analysis.
Carry out validation
studies of AKI coding
to explore this, if
coding is
nondifferential (not
dependent on
exposure status) study
ﬁndings are likely to
be an underestimate
of the true underlying
association.
Remove eGFR values in
week before hospital
admission.
Case control
study
Akin to selection bias in
case-control study
setting if sampling of
control subjects is
restricted to living
individuals.
(i) Control subjects are
not drawn from the
population that case
subjects are derived
from, or
(ii) AKI cases are not
representative of the
population who have
AKI.
Akin to selection bias
in the case-control
setting.
Control subjects may
contain some
undiagnosed cases,
and/or some cases
may not have AKI.
Case status inﬂuences
exposure data
differentially from
those in controls.
Example (i) AKI cases are identiﬁed in a hospital database and compared with control
subjects sampled from primary care, some of whom cannot afford to attend
the hospital that was used to identify cases.
(ii) Only including AKI cases recorded in registry, but the registry has poor
coverage and is more likely to capture cases with CKD.
See example and
corresponding
mitigation above.
See example and
corresponding
mitigation above.
Suggested
mitigation
for example
(i) Source control subjects from a population of hospital attenders.
(ii) Use alternative sources of identifying AKI.
Potential ways that bias may be mitigated are given but are not exhaustive. Potential confounding factors are not listed/discussed in this table but must also be addressed.
AKI, acute kidney injury; CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate.
HI McDonald et al.: Methodological challenges when using routine EHRs m in i r ev i ewsecond creatinine test after 3 months, and therefore CKD
should not be deﬁned at the time of the ﬁrst eGFR mea-
surement. A previous study compared people who had both a
test and a follow-up clinic visit with people who did not
attend the follow-up clinic visit and found that this may
introduce an artiﬁcial survival advantage for those who
attended follow-up of at least 20%.26 Alternatively, the
comparison should be between people who have CKD as
deﬁned by the second eGFR result versus individuals with at
least the same length of follow-up in the database. The “last-
carried-forward” time-updated method used by James et al.27Kidney International (2016) 90, 943–949may be more suitable for studies with follow-up time long
enough for CKD progression to be an issue. In this approach,
CKD stage is deﬁned at any given time using the GFR estimate
produced by the single most recent creatinine result
(Figure 3). This method allows updating of the patient’s
status as CKD progresses. Although creatinine ﬂuctuation
will result in misclassiﬁcation of CKD stage, the patient’s
status will be updated at the next test result, minimizing
misclassiﬁed person-time.
Avoiding selection bias and outcome misclassiﬁcation. The
best way to avoid selection bias is to restrict the study947
Time
Study entry Study exit
eGFR = 58 eGFR = 29 eGFR = 33 eGFR = 22
60–75
45–59
30–44
15–29
<15
Figure 3 | The last-carried-forward method for establishing eGFR
over time according to a patient’s eGFR category. Shaded bars
correspond to the time a patient is thought to have a particular
estimated glomerular ﬁltration rate (eGFR) category, with arrows
representing study entry and times of recorded eGFR results in the
health record.30
min i r ev i ew HI McDonald et al.: Methodological challenges when using routine EHRspopulation to those for whom it is true that if the outcome
occurs, it will be recorded in the participant’s health record,
and that control subjects in a case-control study are drawn
from the same population as the case subjects. If the study
outcome is starting dialysis, then the start date of dialysis
needs to be clearly deﬁned to avoid misclassiﬁcation. For
example, it is important to clarify whether for those on
peritoneal dialysis the start date is the date of insertion of a
peritoneal dialysis catheter or the start of peritoneal dialysis
training. A complicating factor is that the EHRs may span a
period of time over which identiﬁcation (for example, see
Figures 1 and 2) and recording of CKD and AKI change,28
affecting how those records may be interpreted. Features
of patients with AKI recorded at hospital admission may
change over time because AKI is an increasingly recognised
complication in hospitalized patients.29 Exploration of the
time-dependent nature of these issues may require sensitivity
analyses in subsets of the cohort stratiﬁed by calendar
period. Physicians may be actively looking for AKI in at-
risk populations. This can be explored by validation studies
or addressed by sensitivity analyses restricted to at-risk
populations.
Conclusions
Using routine data from EHRs provides potential for large
cohorts to be derived with detailed longitudinal records
to facilitate a wide range of kidney research. However, chal-
lenges exist in terms of availability and validity of measures of
renal function. Understanding what inﬂuences testing and
recording of data is vital when planning research using
routinely collected data. Reporting of observational studies
using EHRs should adhere to the Reporting of Studies Con-
ducted Using Observational Routinely-Collected Health
Data (RECORD) guidelines.6DISCLOSURE
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